Gwenn Hansen, Chief Scientific Officer at Nurix Therapeutics, Inc. (NRIX), sold 5,394 shares at $20.00 ($108K) on 2026-06-25, disclosed to the SEC on 2026-06-25.
Scheduled sale ($108k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| NRIX | SELL | 2026-08-05 | $100K | — | Filing → |
| NRIX | SELL | 2026-08-05 | $109K | — | Filing → |
| NRIX | SELL | 2026-07-30 | $90K | — | Filing → |